The continued growth of medical tourism around the world offers unique opportunities for companies focused on medical biotechnologies and pharmaceuticals that have the potential to drive patient mobility. These include new drugs targeting cancers and chronic illnesses such as diabetes and AIDS, genomic testing and treatment for cancers, and cutting edge innovations such as 3D bioprinting of organs, and bio-absorbable medical devices. Growing the biotech sector is one of China’s top national priorities. It features prominently in the government’s 12th Five-Year Plan – a strategic blueprint of economic policies and priorities designed to drive economic growth and investment in the country from 2010 to 2015. China’s Minister of Health has pledged the country will spend $11.8 billion to further biotech research in the next 5 years, as the country looks forward to its 13th Five-Year Plan. Increasingly, Chinese medical biotech companies and pharmaceuticals are opting for in-licensing of Western-originated projects, and engaging in joint ventures and mergers and acquisitions with international firms. Mergers and acquisitions in China’s health care sector rose to a record $11.3 billion in the first 11 months of 2014, up 13 percent from the $10 billion in the same period a year earlier, according to Dealogic data.
Why attend WMTC Asia-Pacific 2015?